For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
59
views
48
references
 Top references
cited by
66
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      830
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The trigeminovascular system plays a central role in migraine, a condition in need of new treatments. The neuropeptide, calcitonin gene-related peptide (CGRP), is proposed as causative in migraine and is the subject of intensive drug discovery efforts. This study explores the expression and functionality of two CGRP receptor candidates in the sensory trigeminal system.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          The global burden of headache: a documentation of headache prevalence and disability worldwide.

          LJ Stovner, K. Hagen, R. Jensen … (2007)
          This study, which is a part of the initiative 'Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide', assesses and presents all existing evidence of the world prevalence and burden of headache disorders. Population-based studies applying International Headache Society criteria for migraine and tension-type headache, and also studies on headache in general and 'chronic daily headache', have been included. Globally, the percentages of the adult population with an active headache disorder are 46% for headache in general, 11% for migraine, 42% for tension-type headache and 3% for chronic daily headache. Our calculations indicate that the disability attributable to tension-type headache is larger worldwide than that due to migraine. On the World Health Organization's ranking of causes of disability, this would bring headache disorders into the 10 most disabling conditions for the two genders, and into the five most disabling for women.
          Article 0 comments Cited 630 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Migraine--current understanding and treatment.

            Peter J Goadsby, Richard Lipton, Michel D. Ferrari (2002)
            Article 0 comments Cited 273 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

              David W Dodick, Peter J Goadsby, Stephen D. Silberstein … (2014)
              Calcitonin gene-related peptide (CGRP) is crucial in the pathophysiology of migraine. We assessed the safety, tolerability, and efficacy of ALD403, a genetically engineered humanised anti-CGRP antibody, for migraine prevention.
              Article 0 comments Cited 156 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): Ann Clin Transl Neurol
                Title: Annals of clinical and translational neurology
                Publisher: Wiley
                ISSN: 2328-9503
                ISSN (Print): 2328-9503
                Publication date (Electronic): Jun 2015
                Volume: 2
                Issue: 6
                Affiliations
                [1 ] School of Biological Sciences, University of Auckland Auckland, 1142, New Zealand ; Centre for Brain Research, University of Auckland Auckland, 1142, New Zealand.
                [2 ] Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University Lund, Sweden.
                [3 ] Departments of Pharmacology and Medicine, University of California at San Diego La Jolla, California.
                [4 ] Centre for Brain Research, University of Auckland Auckland, 1142, New Zealand ; Department of Anatomy with Radiology, Faculty of Medical and Health Science, University of Auckland Auckland, 1142, New Zealand.
                [5 ] School of Biological Sciences, University of Auckland Auckland, 1142, New Zealand.
                [6 ] Department of Molecular Physiology and Biophysics, University of Iowa Iowa City, Iowa ; Department of Neurology, Veterans Affairs Medical Center, University of Iowa Iowa City, Iowa.
                Article
                DOI: 10.1002/acn3.197
                PMC ID: 4479521
                PubMed ID: 26125036
                SO-VID: 467f3474-ec27-4b99-a3f4-0666d8147b06
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content830

                See all similar

                Cited by63

                See all cited by

                Most referenced authors1,124

                See all reference authors